Prophylaxis of Cytomegalovirus in Renal Transplant Recipients
| Autor: | David Nicol, Philip Belitsky, Spencer Lee, Allan S. MacDonald |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty biology business.industry Incidence (epidemiology) Congenital cytomegalovirus infection virus diseases Disease medicine.disease Gastroenterology lcsh:Infectious and parasitic diseases Renal transplant Internal medicine medicine biology.protein lcsh:RC109-216 Antibody High titre business |
| Zdroj: | Canadian Journal of Infectious Diseases, Vol 4, Iss Suppl C, Pp 51-57 (1993) |
| ISSN: | 1180-2332 |
| DOI: | 10.1155/1993/916208 |
| Popis: | The incidence and outcome of cytomegalovirus (CMV) infection and disease is compared in renal transplant recipients in relation lo the use of prophylaxis wiU1 high titre anti-CMV immunoglobulin. Seventy-three CMV-negative recipients (R-) who received kidneys from CMV-posilive donors (D+) were given prophylactic CMV hyperimmune globulin inlravenously al three-week intervals lo six monilis. They also received Lhree months of oral low dose acyclovir as did the remaining 288 patients who did nol receive hyperimmune globulin. There was a low incidence of CMV disease which did not differ between groups (D+R-, 10%: D+R+, 5 .5%, D- R+, 7%: D- R-, 0.8%). The major risk factor was the use of OKT3 to treat rejection. CMV disease was seen in 22% of this group (11 of 50) . compared with only 2% (seven of 311) of those not requiring OKT3. There was only one CMV-related death. but palients with CMV disease had a reduced graft survival rate (62% versus 90%). CMV hyperimmune globulin added lo acyclovir appears to reduce the incidence of CMV disease in high risk renal recipients (D+R-) in the lower risk groups. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|